These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 2872958)

  • 41. Review of the use of alpha-adrenoceptor antagonists in hypertension.
    Stokes GS; Marwood JF
    Methods Find Exp Clin Pharmacol; 1984 Apr; 6(4):197-204. PubMed ID: 6146746
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin.
    Thomas D; Wimmer AB; Wu K; Hammerling BC; Ficker EK; Kuryshev YA; Kiehn J; Katus HA; Schoels W; Karle CA
    Naunyn Schmiedebergs Arch Pharmacol; 2004 May; 369(5):462-72. PubMed ID: 15098086
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alpha-adrenoceptor blocking drugs and female urinary incontinence: prevalence and reversibility.
    Marshall HJ; Beevers DG
    Br J Clin Pharmacol; 1996 Oct; 42(4):507-9. PubMed ID: 8904625
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical settings for selective alpha-adrenergic receptor inhibition: rationale and management strategies. Proceedings of a symposium. Naples, Florida, October 13 to 16, 1988.
    Am J Med; 1989 Aug; 87(2A):1S-66S. PubMed ID: 2569821
    [No Abstract]   [Full Text] [Related]  

  • 45. Plethysmographic effects of doxazosin in essential hypertensive patients.
    Mozzato MG; Buzzaccarini F; Casolino P; Valle R; Serena L; Rubino N; Casiglia E; Semplicini A; Pessina AC
    J Hypertens Suppl; 1989 Dec; 7(6):S290-1. PubMed ID: 2576669
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Blood pressure and lipid lowering effects of terazosin.
    Rosenthal J
    J Hum Hypertens; 1989 Dec; 3 Suppl 2():85-9; discussion 90-1. PubMed ID: 2575179
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term effects of doxazosin and atenolol on serum lipids and blood pressure in hypertensive smokers.
    Talseth T; Westlie L; Daae LN
    J Hypertens Suppl; 1990 Sep; 8(5):S47-51. PubMed ID: 1981077
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A multicenter study of doxazosin in the treatment of severe essential hypertension.
    Soltero I; Guevara J; Silva H; Velasco M
    Am Heart J; 1988 Dec; 116(6 Pt 2):1767-71. PubMed ID: 2904748
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The pharmacology of antihypertensive drugs with special reference to vasodilators, alpha-adrenergic blocking agents and prazosin.
    Cambridge D; Davey MJ; Massingham R
    Med J Aust; 1977 Aug; 2(1 Suppl):2-6. PubMed ID: 21341
    [No Abstract]   [Full Text] [Related]  

  • 50. Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension.
    Luther RR; Glassman HN; Estep CB; Schmitz PJ; Horton JK; Jordan DC
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):237S-240S. PubMed ID: 2901267
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mechanism of alpha blockade for blood pressure control.
    Davey M
    Am J Cardiol; 1987 May; 59(14):18G-28G. PubMed ID: 2884849
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interactions between enalaprilat and doxazosin at rat tail artery alpha 1-adrenoceptors.
    Marwood J; Tierney G; Stokes G
    J Cardiovasc Pharmacol; 1991 Jan; 17(1):1-7. PubMed ID: 1708041
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects.
    Westheim A; Daae LN; Kierulf P; Brusletto B; Holme I; Syvertsen JO
    J Hypertens Suppl; 1990 Sep; 8(5):S41-6. PubMed ID: 1981076
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antihypertensive dose-response relationships: studies with the selective alpha 1-blocking agent terazosin.
    Weber MA; Cheung DG; Laddu AR; Luther RR
    Am Heart J; 1991 Sep; 122(3 Pt 2):905-10. PubMed ID: 1678921
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
    Kyprianou N
    J Urol; 2003 Apr; 169(4):1520-5. PubMed ID: 12629407
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of doxazosin in hypertension therapy.
    Hayduk K
    Am J Cardiol; 1987 May; 59(14):35G-39G. PubMed ID: 2884851
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alpha 1-blockers, their antihypertensive efficacy and effects on lipids and lipoprotein.
    Kincaid-Smith P
    J Hum Hypertens; 1989 Dec; 3 Suppl 2():75-83. PubMed ID: 2575178
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New alpha 1-adrenergic receptor antagonists for the treatment of hypertension: role of vascular alpha receptors in the control of peripheral resistance.
    Cubeddu LX
    Am Heart J; 1988 Jul; 116(1 Pt 1):133-62. PubMed ID: 2899387
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
    Tahmatzopoulos A; Kyprianou N
    Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical pharmacotherapeutics of doxazosin.
    Taylor SH
    Am J Med; 1989 Aug; 87(2A):2S-11S. PubMed ID: 2569822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.